Oligonucleotide

WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site

Retrieved on: 
Monday, January 8, 2024
Plant, Patient, Drug development, SPPS, Peptide, Oligonucleotide, API, Wuxi, Fine chemical

SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, announced the commissioning of its two new peptide manufacturing plants, one at its Changzhou facility and another at the new Taixing site in China. This significant expansion has increased the company's Solid-Phase Peptide Synthesis (SPPS) total reactor volume to 32,000 liters, addressing the surging global demand for peptide therapeutics.

Key Points: 
  • The other newly commissioned peptide plant is situated at the company's Taixing site.
  • Commissioning the peptide plant at the Taixing site marks its official launch as the newest and largest of WuXi AppTec's five API production sites.
  • Dr. Minzhang Chen, Co-CEO of WuXi AppTec, commented: "The launch of our new peptide manufacturing plants and the development of the new Taixing site are important milestones for WuXi AppTec.
  • WuXi AppTec will continue to focus on enhancing our capability and capacity, accelerating innovative therapies to patients globally."

Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones

Retrieved on: 
Monday, January 8, 2024
Well, RNA, Conference, Science, Wave, Messenger, Research, AAT, Chemistry, Pizzicato, Small RNA, Lung, Weight, Health, Disease, MBA, MD, Mouse, HD, Human, Serum, GSK, Mutation, Genetics, Coronary artery disease, Obesity, Genomics, Concentration ratio, Central nervous system, Patient, Liver disease, Lof, HTT, Medicine, Therapy, Oligonucleotide, NHP, CTA, Vaccine

We expect 2024 will be an inflection year that will drive significant value for Wave, our shareholders, and most importantly, for the patients who will benefit from our research,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences.

Key Points: 
  • We expect 2024 will be an inflection year that will drive significant value for Wave, our shareholders, and most importantly, for the patients who will benefit from our research,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences.
  • Expected milestones: Wave plans to deliver proof-of-mechanism data in individuals with AATD in 2024.
  • Expected milestones: Wave expects to deliver data, including dystrophin protein expression from muscle biopsies at 24 weeks, in the third quarter of 2024.
  • A live webcast of this presentation will be available on the Investor Relations page of the Wave Life Sciences website at http://ir.wavelifesciences.com .

Oligo Factory Announces GMP Compliance

Retrieved on: 
Wednesday, January 3, 2024
Health, Health Technology, Other Science, General Health, Science, Pharmaceutical, Biotechnology, Documentation, GMP, Good manufacturing practice, Drug discovery, Oligonucleotide, Quality control, Multimedia, Factory, Fine chemical

Oligo Factory, a leading manufacturer of high-quality oligonucleotides at scale, announces today that it is compliant with current Good Manufacturing Practices (GMP).

Key Points: 
  • Oligo Factory, a leading manufacturer of high-quality oligonucleotides at scale, announces today that it is compliant with current Good Manufacturing Practices (GMP).
  • Oligo Factory has implemented a comprehensive quality management system to align its operations with GMP guidelines.
  • I’m extremely proud of our team who worked tirelessly throughout 2023 to achieve this milestone," said Chris Boggess, CEO of Oligo Factory.
  • In early 2023, Oligo Factory opened a state-of-the-art oligonucleotide synthesis facility in Holliston, MA, to meet growing demand for its services.

Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

Retrieved on: 
Wednesday, December 27, 2023
Liver, RNA interference, LNC, Small RNA, PCR, DSS, Inflammation, Serum, Animal, IL-17A, Commensurability, Colitis, Imiquimod, Lecture, Psoriasis, Oligonucleotide, Therapy, Vaccine

BEDMINSTER, N.J, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform technology, announces results from a series of in vivo studies demonstrating successful oral delivery of two LNC-formulated small single-strand oligonucleotides that specifically target key inflammatory cytokines TNFα and IL-17A in well-established and validated animal models that mimic acute inflammatory responses seen in human diseases.

Key Points: 
  • Commensurate improvements in clinical disease markers and scores were also documented in both models,” said James Ferguson, M.D., Matinas’ Chief Medical Officer .
  • “While additional study is warranted, the successful oral delivery of small oligonucleotides is very exciting and we believe these data demonstrate how Matinas’ LNC platform could be used for the oral delivery of functional small oligonucleotides with potential therapeutic applications,” Dr. Ferguson added.
  • Both were advanced to in vivo studies to evaluate meaningful biological activity in relevant disease models.
  • In this model, while IL-17A serum levels were not expected to change, improvement was demonstrated in clinical disease markers of skin redness and scaling, further validating the biological activity of these small oligonucleotides.

Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033 - Strong Growth by 2033 with a Focus on Treating Rare Diseases - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 27, 2023
Other Health, Research, Pharmaceutical, Genetics, Science, Cardiology, Chemicals, Plastics, Biotechnology, Neurology, Manufacturing, Other Science, Health, Asos, Drug development, Prevalence, Hope, Patient safety, Therapy, DSM-IV codes, Full, Field, Patient, Availability, Oligonucleotide, Immunogenicity, Rare disease

The "Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033" has been added to ResearchAndMarkets.com's offering.
  • World revenue for the Antisense Oligonucleotide (ASO) Therapeutics Market is forecast to surpass US$6 billion in 2023, with strong revenue growth through to 2033.
  • Rare diseases, often referred to as orphan diseases, are characterized by their low prevalence in the population, making them less attractive for traditional drug development efforts.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Antisense Oligonucleotide (ASO) Therapeutics prices and recent developments.

JCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo® Technology

Retrieved on: 
Thursday, December 21, 2023
General Health, Health, Science, Other Science, Research, AstraZeneca, Antibody, BBB, Tissue, JCR, Neurodegenerative disease, Enzyme, Central nervous system, Alexion, Peptide, Therapy, Oligonucleotide, Pharmaceutical industry

Under the terms of the agreement, JCR and Alexion will research and develop oligonucleotide therapeutics using J-Brain Cargo® Technology.

Key Points: 
  • Under the terms of the agreement, JCR and Alexion will research and develop oligonucleotide therapeutics using J-Brain Cargo® Technology.
  • As part of the collaboration, Alexion may nominate up to three targets in rare disease indications for pre-clinical development using the platform.
  • Following pre-clinical development, Alexion will have the option to develop and commercialize the potential new drug candidates.
  • The collaboration is the second agreement between JCR and Alexion in 2023, following a March announcement regarding a research collaboration, option and license agreement to develop therapeutic protein candidates using J-Brain Cargo® for neurodegenerative disease.

PharmaBlock Opens HPAPI GMP Facility at Zhejiang Manufacturing Site

Retrieved on: 
Wednesday, December 27, 2023
Multimedia, API, Research, Spacecraft, OEL, CMC, Occupational exposure limit, GMP, Peptide, Oligonucleotide, ADC, Fine chemical

NANJING, China, Dec. 26, 2023 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725.SZSE), a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has announced opening of a new high potency API (HPAPI) GMP facility (OEB-5 and above) at its Zhejiang manufacturing site.

Key Points: 
  • NANJING, China, Dec. 26, 2023 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725.SZSE), a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has announced opening of a new high potency API (HPAPI) GMP facility (OEB-5 and above) at its Zhejiang manufacturing site.
  • The new HPAPI GMP facility enables PharmaBlock to offer process R&D and kilo-scale production of HPAPIs and ADC toxins.
  • In addition to this new GMP HPAPI facility, multiple workshops at PharmaBlock Zhejiang are capable to manufacture OEB-4 compounds.
  • The new HPAPI GMP facility is a crucial addition to support the delivery of ADC projects to global partners.

QPS Continues UPLC-HRMS Expansion Into Europe to Support Gene Therapy and Protein Drug Development

Retrieved on: 
Thursday, December 14, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Chem, Tandem mass spectrometry, QPS, Chemistry, GLP, University of California, Berkeley, Peptide, Physikalisch-Technische Bundesanstalt, Diples, Multimedia, Daniel, LC-MS, Master of Science, Therapy, University of Kassel, Mass spectrometry, Drug discovery, University, Doctor of Philosophy, Biomarker, Oligonucleotide, UC, Drug development, LC-MS/MS, Fine chemical, Medtronic, Bioanalysis

QPS announces an expanded and upgraded fleet of mass spectrometers, with the addition of a new TripleTOF® 6600+ for GLP quantitation in Groningen, The Netherlands.

Key Points: 
  • QPS announces an expanded and upgraded fleet of mass spectrometers, with the addition of a new TripleTOF® 6600+ for GLP quantitation in Groningen, The Netherlands.
  • This is a natural extension of 20+ years of supporting oligonucleotide drug development using LC-(HR)MS/MS in our Newark, Delaware, USA facility,” said Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC.
  • This has become an even higher priority with the explosion of work being done in the nucleic acid therapeutics and protein drug development arena,” said Daniel Schulz-Jander, MSc, PhD, Senior Director of Bioanalysis, QPS Netherlands.
  • With this expansion, this group now has all the necessary LC-MS and other chromatographic technology for PK/PD bioanalysis to support clients in drug discovery and development of gene therapies and protein drug development.

Gene Therapy Research Report 2023: Market Analysis by Gene Silencing, Gene Augmentation, Vector, Therapeutic Area, Delivery Method, RoA - Global Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 17, 2023
Biotechnology, Pharmaceutical, Genetics, Health, Biogen, Research, Conditional sentence, Oligonucleotide, Prevalence, Gilead Sciences, Retrovirus, Growth, Neurology, Bristol Myers Squibb, USD, Therapy, Novartis, Cancer, Region, Gene silencing, Government, AAV, Intravenous therapy, Pharmaceutical industry

The "Gene Therapy Market by Type (Gene silencing, Gene augmentation), Vector (Viral (Retroviral, AAV), Non-viral (Oligonucleotide)), Therapeutic Area (Neurology, Oncology), Delivery Method (In-vivo, Ex-vivo), RoA (Intravenous) & Region - Global Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gene Therapy Market by Type (Gene silencing, Gene augmentation), Vector (Viral (Retroviral, AAV), Non-viral (Oligonucleotide)), Therapeutic Area (Neurology, Oncology), Delivery Method (In-vivo, Ex-vivo), RoA (Intravenous) & Region - Global Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The growth of the gene therapy market is driven by several key factors, including increasing initiatives in genomic research and a growing number of regulatory approvals for gene therapy products.
  • Based on type, the gene therapy market is categorized into neurology, oncology, hepatology, and other therapeutic areas..
  • Based on end user, the gene therapy market is segmented into the gene therapy market is segmented into in vivo and ex vivo.

Synthetic biology market size to grow by USD 28.25 billion from 2022 to 2027, the evolving regulatory framework around synthetic biology is the market trend - Technavio

Retrieved on: 
Wednesday, December 13, 2023
Medicine, Agriculture, Safety, Gene, MIT, Microbiology, ROW, Investment, Risk, Food, Government, F&B, Protein, TSCA, Biofuel, USD, Health, Nutrient, Therapy, Synthetic biology, Massachusetts Institute of Technology, Nitrogen fixation, Geography, Water, Growth, Oligonucleotide, Environment, Enzyme, Fine chemical, Speciality chemicals, COVID-19

NEW YORK, Dec. 12, 2023 /PRNewswire/ -- The global synthetic biology market size is estimated to grow by USD 28.25 billion from 2022 to 2027, according to Technavio.

Key Points: 
  • NEW YORK, Dec. 12, 2023 /PRNewswire/ -- The global synthetic biology market size is estimated to grow by USD 28.25 billion from 2022 to 2027, according to Technavio.
  • The evolving regulatory framework around synthetic biology is a key trend in the market.
  • Therefore, the evolving regulatory framework for synthetic biology is expected to promote investments, foster innovation, and ensure the safety and efficacy of synthetic biology products, which, in turn, will support market growth during the forecast period.
  • The report provides actionable insights and estimates the contribution of all regions to the growth of the global synthetic biology market.